Wedbush Morgan Upgrades Abiomed (ABMD) to Neutral; Potential Near-Term Catalysts
Tweet Send to a Friend
Wedbush Morgan upgrades Abiomed (Nasdaq: ABMD) from Underperform to Neutral. Price target $12.
Wedbush analyst says, "In the absence ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "In the absence ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
